sponsored
PatientsVille.com Logo

PatientsVille

Cosmegen Medical Research Studies

Up-to-date List of Cosmegen Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Cosmegen Medical Research Studies

Rank Status Study
1 Recruiting Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Conditions: Gestational Trophoblastic Tumor;   Hydatidiform Mole;   Low Risk Metastatic Gestational Trophoblastic Tumor;   Uterine Choriocarcinoma
Interventions: Drug: leucovorin calcium;   Biological: dactinomycin;   Drug: methotrexate;   Procedure: quality-of-life assessment
Outcome Measures: Complete response vs treatment failure;   Severity of adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4;   Overall QOL
2 Recruiting Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
Condition: Melanoma
Intervention: Drug: Ipilimumab, Melphalan and Dactinomycin
Outcome Measures: To determine progression free survival at one year.;   To determine the safety of additional Ipilimumab. Safety will be evaluated for all treated patients using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0;   To determine response rates of combination therapy. Tumor assessment will be measured by the immune related response criteria (irRC).;   To define the immunologic events and signatures at the tumor site and in the periphery that corresponds to response to Ipilimumab.
3 Recruiting Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia
Conditions: Gestational Trophoblastic Disease;   Gestational Trophoblastic Neoplasia;   Gestational Trophoblastic Tumor;   Gestational Trophoblastic Neoplasms
Interventions: Drug: MTX 1;   Drug: MTX 2;   Biological: Act-d
Outcome Measures: Severity of adverse events as assessed by the WHO;   Progression-Free Survival (PFS);   Complete response vs treatment failure;   Resume menstruation;   The pregnancy rate;   the delivery rate with at least one live born baby;   The incidence of abnormal pregnancy
4 Unknown  A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer
Condition: Cancer
Interventions: Drug: Actinomycin-D;   Drug: Vincristine
Outcome Measure: Characterization of Plasma Pharmacokinetics to examine the optimal dosing, metabolites and inter-patient variability of actinomycin-D in children with cancer during any sample of chemotherapy.
5 Recruiting Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery
Condition: Rhabdomyosarcoma
Interventions: Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Procedure: Surgical Resection;   Procedure: Radiation;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Myeloid Growth Factor;   Procedure: Lymph Node Sampling
Outcome Measures: Event-free survival;   Rate of false negative and false positive the sentinel lymph node procedure;   Local failure rate;   Patterns of failure;   Number of patients that complete all cycles of maintenance chemotherapy;   Incidence of CTC grade 3 and higher toxicities related to proton bream therapy
6 Not yet recruiting Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
Condition: Melanoma
Interventions: Biological: dactinomycin;   Drug: melphalan;   Biological: Conditionally replicative adenovirus 3/5-delta
Outcome Measures: Optimal tolerated dose (OTD) of CRAd 3/5;   Response rate (complete response [CR] + partial response [PR]) of CRAd 3/5-delta in combination with standard M-ILI (Phase II);   Progression Free Survival (Phase II);   Safety of CRAd 3/5-delta in combination with standard M-ILI;   Infectivity rate of CRAd 3/5-delta
7 Unknown  Pharmacokinetics of Dactinomycin in Young Patients With Cancer
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Genetic: molecular genetic technique;   Other: mass spectrometry;   Other: pharmacological study
Outcome Measures: Pharmacokinetics (PKs) of dactinomycin;   Degree of interpatient variation of drug PKs;   Influence of characteristics such as age, tumor type, and concurrent therapy on drug PKs;   Correlation of drug PKs with clinical response and toxicity, particularly the incidence of severe liver toxicity or veno-occlusive disease
8 Unknown  Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma
Condition: Sarcoma
Interventions: Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate
Outcome Measures: Disease-free survival at 3 years after study registration;   Overall survival at 3 years after study registration;   Toxicity by NCI CTC at 3 years after study registration
9 Unknown  Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma
Condition: Sarcoma
Interventions: Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Radiation: radiation therapy
Outcome Measures: Disease-free survival as measured by Kaplan-Meier method 3 years after study entry;   Overall survival as measured by Kaplan-Meier method 3 years after study entry;   Progression-free survival as measured by Kaplan-Meier method during events;   Complete response rate (orbit, group III only) at completion of study treatment;   Rate of toxicity as measured by NCI-CTC v 2.0 3 years after study entry
10 Recruiting Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Conditions: Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Stage I Wilms Tumor;   Stage II Wilms Tumor;   Stage III Wilms Tumor;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Drug: doxorubicin hydrochloride;   Procedure: therapeutic conventional surgery;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: carboplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy
Outcome Measures: Event-free survival;   Prevention of complete removal of at least one kidney in 50% of patients with bilateral Wilms tumor (BWT);   Efficacy of chemotherapy in preserving renal units and preventing Wilms tumor development in patients with diffuse hyperplastic perilobular nephrogenic rests;   Facilitation of partial nephrectomy in lieu of total nephrectomy in 25% of patients with unilateral Wilms tumor;   Percentage of patients with BWT undergoing definitive surgical treatment by week 12
11 Recruiting International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry
Condition: Pleuropulmonary Blastoma
Interventions: Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Doxorubicin
Outcome Measures: Event-free survival;   Overall response to chemotherapy, and survival
12 Recruiting Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
Condition: Ewing's Sarcoma
Interventions: Drug: Standard treatment (as per protocol ISG SSG III);   Drug: Intensified chemotherapy
Outcome Measures: Event Free Survival (EFS);   Disease Free Survival (DFS);   Metastasis Free Survival;   Overall Survival (OS)
13 Unknown  Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
Condition: Sarcoma
Interventions: Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Outcome Measures: Event-free survival;   Overall survival;   Feasibility, toxicity, and response at 1 month following induction therapy;   Feasibility and toxicity of consolidation regimens at 1 month following consolidation therapy
14 Recruiting A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis
Condition: Germ Cell Tumour
Intervention: Drug: Combination Chemotherapy
Outcome Measures: Objective response rate;   Progression Free Survival;   Overall Survival;   Toxicity Level
15 Unknown  Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor
Condition: Kidney Cancer
Interventions: Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
Outcome Measures: Event-free survival;   Treatment failure, in terms of disease recurrence or death
16 Unknown  Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma
Condition: Sarcoma
Interventions: Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: vinorelbine tartrate;   Procedure: conventional surgery;   Radiation: radiation therapy
Outcome Measures: Event-free survival;   Disease-free survival (in patients treated with maintenance chemotherapy);   Overall survival;   Progression-free survival;   Response rate;   Toxicity as measured by NCI-CTC version 3

These studies may lead to new treatments and are adding insight into Cosmegen etiology and treatment.

A major focus of Cosmegen research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Cosmegen